Market Place
Sourcing Support
Merck lines up $70B+ in revenue opportunities over next decade
04 Feb 2026 //
FIERCE PHARMA
FDA Accepts BLA for Ivonescimab Combo in NSCLC Post-TKI Therapy
30 Jan 2026 //
PRESS RELEASE
Kazia Shows Positive Early Results In Phase 1B Paxalisib Study
27 Jan 2026 //
PR NEWSWIRE
Blau Pharma Fully Develops Advanced Biosimilar Immunotherapy
23 Jan 2026 //
PR NEWSWIRE
Adagene Provides Business Update And 2026 Objectives
23 Jan 2026 //
GLOBENEWSWIRE
Merck, Moderna Sustain 49% Melanoma Risk Reduction At 5 Years
22 Jan 2026 //
FIERCE BIOTECH
NEJM: Ph 3 ASCENT-04/KEYNOTE-D19 Trodelvy+Keytruda Supports SoC
21 Jan 2026 //
BUSINESSWIRE
Immunomic Therapeutics Receives FDA Clearance For Unite RNA
20 Jan 2026 //
BUSINESSWIRE
ImmunityBio`s ANKTIVA Pairs with Checkpoint Inhibitors for NSCLC
13 Jan 2026 //
PHARMIWEB
Merck Confident In Growth Despite Keytruda Exclusivity Loss
13 Jan 2026 //
BIOSPACE
Merck Starts Phase 3 Trial Of Calderasib With Keytruda For NSCLC
11 Jan 2026 //
INDPHARMAPOST
Cytomx Therapeutics Unveils 2026 Business Update And Milestones
08 Jan 2026 //
GLOBENEWSWIRE
Merck Starts Phase 3 Trial of KRAS G12C Drug With Keytruda QLEX
07 Jan 2026 //
PHARMIWEB
BBOT Advances RAS And Pi3K? Pipeline With New Clinical Data
07 Jan 2026 //
GLOBENEWSWIRE
Biocon Biologics Launching Three New Cancer Biosimilars
06 Jan 2026 //
ECONOMICTIMES
Kelun Biotech Secures China`s BTD for Sac-TMT/Pembro in PD-L1+ GC
05 Jan 2026 //
PR NEWSWIRE
Bioinvent Reveals Positive Phase 2A Results For BI-1808
05 Jan 2026 //
PHARMIWEB
Pyxis Oncology Reports Positive Ph 1 Results For MICVO In Cancer
18 Dec 2025 //
GLOBENEWSWIRE
Astellas` PADCEV And Keytruda Boost Survival in Bladder Cancer
17 Dec 2025 //
PR NEWSWIRE
Inhibrx Biosciences Updates INBRX-106 And Ozekibart Expansion
16 Dec 2025 //
PR NEWSWIRE
Adagene Reveals FDA Fast Track For Muzastotug In Cancer
16 Dec 2025 //
GLOBENEWSWIRE
Medicenna Enhances MDNA11 Trial Results At ESMO-IO Congress
10 Dec 2025 //
GLOBENEWSWIRE
Medicenna Therapeutics Hosts Live Webinar On Updated MDNA11
09 Dec 2025 //
GLOBENEWSWIRE
Zydus, Formycon Partner For Exclusive Biosimilar Supply
09 Dec 2025 //
PR NEWSWIRE
Halozyme Wins German Injunction Blocking Keytruda Distribution
08 Dec 2025 //
INDPHARMAPOST
Bioinvent Unveils Positive Phase 2A BI-1808 Monotherapy Results
07 Dec 2025 //
PHARMIWEB
Bicara Phase 1b Data Supports Ficerafusp Dose for Pivotal Study
06 Dec 2025 //
GLOBENEWSWIRE
Merck`s Keytruda SC Launch In Germany Faces Legal Hurdle
05 Dec 2025 //
FIERCE PHARMA
Pliant Therapeutics: Interim PLN-101095 Data for Immune Diseases
04 Dec 2025 //
GLOBENEWSWIRE
Halozyme Secures Injunction On Merck`s Keytruda SC In Germany
04 Dec 2025 //
PR NEWSWIRE
Formycon, MS Pharma Partner On Exclusive Keytruda Biosimilar
04 Dec 2025 //
PR NEWSWIRE
Bicara Therapeutics Publishes Phase 1b Data On Ficerafusp Alfa
01 Dec 2025 //
GLOBENEWSWIRE
Kelun-Biotech Initiates Phase III Trial For SAC-TMT with Keytruda
24 Nov 2025 //
PR NEWSWIRE
FDA Approves Combo Therapy For Ineligible Bladder Cancer Patients
23 Nov 2025 //
INDPHARMAPOST
Merck Gets EU Approval For First Subcutaneous Cancer Treatment,
21 Nov 2025 //
INDPHARMAPOST
FDA Approves Padvec & Keytruda Combo For Bladder Cancer
21 Nov 2025 //
BUSINESSWIRE
EU Approves Subcutaneous Keytruda for All Adult Indications
19 Nov 2025 //
BUSINESSWIRE
Kazia Therapeutics Hits Initial iCR in Metastatic TNBC
19 Nov 2025 //
PR NEWSWIRE
First Patient Dosed in SYNERGY-101 Ph2 Trial of STK-012
13 Nov 2025 //
BUSINESSWIRE
FDA Clears Promega OncoMate MSI As CDx For Keytruda + Lenvima
11 Nov 2025 //
BUSINESSWIRE
AIM Immunotech Reveals UPMC Abstract On Ampligen`s Role
10 Nov 2025 //
GLOBENEWSWIRE
Synthekine Reveals Positive Phase 1A/1B Trial Results
07 Nov 2025 //
BUSINESSWIRE
Flare Therapeutics Presents FX-909 Ph1A Biomarker Analysis
07 Nov 2025 //
GLOBENEWSWIRE
Ileukon Gets FDA Nod For Phase II mRNA Study In Advanced NSCLC
04 Nov 2025 //
PR NEWSWIRE
Cytomx To Unveil CX-801 Phase 1 Biomarker Data At SITC Meeting
04 Nov 2025 //
GLOBENEWSWIRE
Eisai Shows Dedication To Advanced Endometrial Cancer Care
03 Nov 2025 //
PR NEWSWIRE
Adagene Doses First Patient in Ph2 Muzastotug Combo Study
31 Oct 2025 //
GLOBENEWSWIRE
Synthekine to Present STK-012 Combo Data in NSCLC at SITC 2025
30 Oct 2025 //
BUSINESSWIRE
Destiny-Lung06 Trial Begins: Enhertu Phase 3 For 1St-Line HER2
30 Oct 2025 //
BUSINESSWIRE
EC Approves Keytruda Combo for PD-L1+Resectable Head&Neck Cancer
29 Oct 2025 //
BUSINESSWIRE
Merck, Eisai End Keytruda-Lenvima Collaboration In Liver Cancer
29 Oct 2025 //
FIERCE PHARMA
Welireg`s RCC Wins Could Pad Merck`s Post-Keytruda Sales
28 Oct 2025 //
FIERCE PHARMA
FDA Prioritizes KEYTRUDA And KEYTRUDA QLEX Combo with Padcev
23 Oct 2025 //
BUSINESSWIRE
MDNA11 Clinical Data From ABILITY-1 Study At ESMO 2025
23 Oct 2025 //
GLOBENEWSWIRE
HCW Biologics Joins Virtual Investor Segment
22 Oct 2025 //
GLOBENEWSWIRE
Keytruda, Lenvima Show Long-Term Survival Benefit in Cancer
22 Oct 2025 //
INDPHARMAPOST
Flare Pharma Collaborates with Merck for Fx-909 and Keytruda
21 Oct 2025 //
GLOBENEWSWIRE
KEYTRUDA® Shows Prolonged Survival Benefit In Some NSCLC Patients
20 Oct 2025 //
BUSINESSWIRE
Immunos Therapeutics Shows IOS-1002 Promise In Advanced Solid
20 Oct 2025 //
PHARMIWEB
Transgene & BioInvent’s BT-001 Shows Strong Antitumor Activity
20 Oct 2025 //
ACCESSWIRE
